Kamada Ltd. Logo

Kamada Ltd.

Develops specialty plasma-derived therapeutics for rare and serious conditions.

KMDA | TA

Overview

Corporate Details

ISIN(s):
IL0010941198
LEI:
Country:
Israel
Address:
2 Holzman St, Science Park, 7670402 Rehovot
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kamada Ltd. is a vertically integrated global biopharmaceutical company focused on specialty plasma-derived therapeutics. The company develops, produces, and markets a portfolio of pharmaceuticals for rare and serious conditions, utilizing a proprietary platform technology for the extraction and purification of proteins from human plasma. Its key therapeutic areas include Alpha-1 Antitrypsin Deficiency (AATD), rabies prophylaxis, and prevention of cytomegalovirus (CMV) in transplant recipients. Kamada maintains a diverse portfolio of marketed products and a robust development pipeline, supported by industry-leading manufacturing and protein separation capabilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 15:00
Foreign Filer Report
Kamada Reports Third Quarter and Nine Month 2025 Financial Results
English 4.6 MB
2025-11-10 15:00
Foreign Filer Report
Kamada Reports Third Quarter and Nine Month 2025 Financial Results
English 36.7 KB
2025-11-04 15:00
Foreign Filer Report
Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical…
English 1.2 MB
2025-11-04 15:00
Report Publication Announcement
Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical…
English 36.6 KB
2025-11-03 15:00
Report Publication Announcement
Will release financial results for the third quarter 2025, on November 10, 202…
English 507.8 KB
2025-11-03 15:00
Foreign Filer Report
Will release financial results for the third quarter 2025, on November 10, 202…
English 36.5 KB
2025-10-29 14:00
Report Publication Announcement
Kamada to Present at the Stifel 2025 Healthcare Conference
English 131.2 KB
2025-10-29 14:00
Foreign Filer Report
Kamada to Present at the Stifel 2025 Healthcare Conference
English 36.5 KB
2025-10-23 16:12
Proxy Solicitation & Information Statement
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 10, 202…
English 128.2 KB
2025-10-23 16:12
Foreign Filer Report
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 10, 202…
English 523.5 KB
2025-10-23 16:12
Pre-Annual General Meeting Information
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 10, 202…
English 192.1 KB
2025-10-23 16:04
Foreign Filer Report
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 10, 202…
English 523.5 KB
2025-10-23 16:04
Foreign Filer Report
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 10, 202…
English 36.4 KB
2025-09-02 16:03
Foreign Filer Report
Kamada to Participate in Upcoming September Investor Conferences
English 135.5 KB
2025-09-02 16:03
Foreign Filer Report
Kamada to Participate in Upcoming September Investor Conferences
English 36.3 KB

Automate Your Workflow. Get a real-time feed of all Kamada Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kamada Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kamada Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America
ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom
ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.